Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse

Clifford W. Mason, Hazem E. Hassan, Kang-Pil Kim, Jianjing Cao, Natalie D. Eddington, Amy Hauck Newman, Pamela J. Voulalas

Pharmacokinetics-Biopharmaceutics Laboratory, Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland, USA (C.W.M., H.E.H., K.P.K., N.D.E, P.J.V.), Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Helwan University, Helwan, Egypt (H.E.H.), Medicinal Chemistry Section, National Institution on Drug Abuse, Intramural Research Program, National Institute of Health, Baltimore, MD 21201 (J.C., A.H.N)
RUNNING TITLE PAGE

a) Running Title: Characterization of the DA D3 receptor analogs

b) Corresponding Author:

Pamela J. Voulalas, Ph.D., University of Maryland, 20 Penn Street, HSFII-559, Baltimore, MD 21201 USA
Tel: (410) 706-2097
Fax: (410) 706-5017
Email: pvoulala@rx.umaryland.edu

c) Number of:

Text pages: 43
Tables: 3
Figures: 6
References: 36
Words in Abstract: 247
Words in Introduction: 749
Words in Discussion: 1,493

d) Abbreviations: BBB, blood brain barrier, B/P, brain-to-plasma, DA, dopamine, DAT, dopamine transporter, DA D3R, dopamine D3 receptor, i.p., intraperitoneal, i.v., intravenous,

e) Section assignment: Metabolism, Transport, and Pharmacogenomics
ABSTRACT

The recent discovery of novel high affinity and selective dopamine D3 receptor (DA D3R) antagonists and partial agonists has provided tools with which to further elucidate the role DA D3R plays in substance abuse. The present study was conducted to evaluate the transport, metabolism, pharmacokinetics and brain uptake of the DA D3R selective fluorenyl amides, NGB 2904 and JJC 4-077, and the 2-pyridylphenyl amides, CJB 090 and PG 01037, all of which have been studied in animal models of psychostimulant abuse. Additional screening with a panel of human and rat Supersomes was performed for NGB 2904 and PG 01037. Drug stimulated ATPase activation assays and bidirectional transport and efflux assays were used to test for substrate specificity of NGB 2904 and PG 01037 for human and rat efflux transporters. All compounds exhibited moderate elimination half-lives, ranging from 1.49-3.27 hrs, and large volumes of distribution (5.95-14.19 l/kg). The brain-to-plasma ratios ranged from 2.93-11.81 and were higher than that previously reported for cocaine. Brain exposure levels of NGB 2904 and PG 01037 were significantly reduced following i.p. administration compared to i.v. administration. The metabolism of these compounds was mediated primarily by CYP3A subfamilies. PG 01037 was a P-gp transported substrate. Higher doses of these compounds are often required for in vivo action suggesting decreased bioavailability via extravascular administration which may be attributed to high drug efflux and hepatic metabolism. These studies provide important preclinical information for optimization of next generation D3R selective agents for the treatment of drug addiction.
INTRODUCTION

Cocaine and methamphetamine are potent central nervous system stimulants known for their abuse potential and addictive liability. Cocaine’s effects are shorter than that of methamphetamine (half-life 0.5 hr for cocaine and 11 hr for methamphetamine) making its high abuse liability and chronic use a significant health concern. Despite numerous controlled studies of more than 60 medications, there is currently no conclusive data to support the efficacy of any particular pharmacological agent to treat cocaine abuse (Ross and Peselow, 2009).

For decades, it has been known that the reinforcing effects produced by cocaine and other psychostimulants is associated with activation of DA receptors but elucidating the role of the individual dopamine receptor subtypes D1-D5 has been hampered by the lack of subtype-selective ligands. The discrete location of the dopamine D3 receptors in rodent and human brain, coupled with evidence that their expression is modified following long-term exposure to drugs of abuse, suggest a role for this dopamine receptor subtype in drug addiction (for reviews see (Heidbreder et al., 2005; Newman et al., 2005)). According to recent reports from imaging studies in humans and non-human primates, DA D3Rs may play an important role in the abuse-related effects of cocaine (Volkow et al., 2004; Schwarz et al., 2007). Support for pursuing the DA D3Rs as novel targets for drug abuse pharmacotherapies comes from the hypothesis that selective blockade of DA D3Rs may antagonize drug reward and/or reinforcement while obviating the possibility of extrapyramidal side effects typically associated with the blockade of DA D2Rs (Sokoloff et al., 1990). Studies have also linked the D3 receptors to L-DOPA-induced dyskinesia in Parkinson’s Disease (Kumar et al., 2009; Visanji et al.,
2009) and behavioral aberrations associated with schizophrenia (Richtand, 2006) suggesting additional utility of D3 receptor ligands.

Significant research efforts have been directed toward the development of selective DA D3R agents (Micheli, 2008), yielding novel antagonists and partial agonists with high affinity and selectivity for D3R. Important structure-activity relationships (SAR) have been derived from the 4-phenylpiperazine class of DA D3R ligands, based on prototypic BP897 (N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]naphthalene-2-carboxamide (Pilla et al., 1999) and NGB 2904 (N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide fumarate) (Yuan et al., 1998) and have been reviewed (Boeckler and Gmeiner, 2006). Both these compounds, and an NGB 2904 analog CJB 090 have demonstrated efficacy in animal models of drug abuse (Gilbert et al., 2005; Xi et al., 2006; Martelle et al., 2007; Spiller et al., 2008). For example, NGB 2904 attenuated cue-induced reinstatement of cocaine self administration (Gilbert et al., 2005) and inhibited the enhancement of cocaine- (Xi et al., 2006) or methamphetamine-enhanced brain stimulation reward in rats (Spiller et al., 2008). Further, CJB 090 (Newman et al., 2003) attenuated the discriminative stimulus effects of cocaine and decreased cocaine- maintained responding in rhesus monkeys, without cocaine-like effects (Martelle et al., 2007). Another compound, PG 01037 has been shown to effectively reduce methamphetamine’s rewarding efficacy for drug-seeking behaviors in rats (Higley et al., 2010). NGB 2904, PG 01037, and CJB 090 were effective in all of these animal models at doses that did not induce adverse motor side effects associated with nonselective D2-like antagonists (Achat-Mendes et al., 2009; Higley et al., 2010).
Nevertheless, high doses of these ligands were required in some cases to elicit \textit{in vivo} action, despite phMRI studies showing that significantly lower doses localize in DA D3R-rich regions of the brain (Grundt et al., 2007). It is not known whether the need for higher doses is due to low BBB permeability, high peripheral metabolism or large distribution of these agents into other tissues. Thus, \textit{in vivo} pharmacokinetic and brain uptake studies were conducted in rats on NGB 2904 and three analogs (JJC 4-077 (N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)-9H-fluorene-2-carboxamide hydrochloride), CJB 090 (N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridine-2-yl)benzamide hydrochloride) and PG 01037 (N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-trans-but-2-enyl)-4-(pyridine-2-yl)benzamide hydrochloride). In addition, \textit{in vitro} transport and metabolism studies were undertaken using the DA D3R antagonists NGB 2904 and PG 01037 as representatives of the fluorenyl amide and 2-pyridylphenyl amide groups, respectively, in a screen of a series of human and rat cytochrome P450 enzymes to understand mechanisms for elimination of these agents. Interactions with the efflux transporters were also assessed to determine the potential impact of drug efflux on their permeability at the BBB.

D3R-selective molecules have typically suffered from suboptimal physical properties such as poor water solubility, undesirable pharmacokinetics, predicted metabolism, or side effects unrelated to D3 receptor binding which have prevented their \textit{in vivo} investigation or marred interpretation of results. The goal of the current study was to identify the structural motif(s) responsible for undesirable bioavailability properties, thus guiding future drug design.
METHODS

Materials

Four compounds were analyzed in this study: NGB 2904, JJC 4-077, CJB 090, and PG 01037. PG 01030 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-trans-but-2-enyl)-benzothiopen-2-carboxamide hydrochloride] was used as an internal standard. Figure 1 depicts the structures of the five compounds. 2-hydropropyl-β-cyclodextrin (HPBCD) and polyethyleneglycol 400 (PEG 400) were purchased from Sigma-Aldrich Inc. (St. Louis, MO). Saline (0.9% sodium chloride) was obtained from Baxter (Deerfield, IL). Acetonitrile was purchased from American Bioanalytical (Natick, MA). All chemicals and solvents were of HPLC-grade. Water was obtained from a Barnstead water purification system (Thermo Scientific, Dubuque, IA). MDCK-MDR1 cells were a gift from Dr. Peter Swaan (University of Maryland, Baltimore, MD). Cell culture supplies [Dulbecco’s modified Eagle’s medium, phosphate-buffered saline with Ca^{2+} and Mg^{2+} (PBS), 100x L-glutamine, nonessential amino acids, fetal bovine serum, 0.25% trypsin-1 mM EDTA, and penicillin G-streptomycin sulfate antibiotic mixture] were purchased from Invitrogen (Carlsbad, CA). [^{14}C]-Mannitol (46 mCi/mmols), sodium phosphate dibasic and verapamil HCl, were purchased from Sigma-Aldrich (St. Louis, MO). [^{3}H]-Saquinavir (3500 mCi/mmols) was purchased from Moravek Biochemicals (Brea, CA). Transwell clusters were purchased from Corning Life Sciences (Acton, MA). Human and rat P-gp, BCRP, and MRP2 Spodotera frugiperda (Sf9) membranes and microsomes from baculovirus-infected insect cells expressing human CYP1A2, 2A6, 2B6, 2C8, 2C9*1(Arg144), 2C19, 2D6*1, 2E1, and 3A4 and rat CYP1A2, 2B1, 2C11, 2D1, 2E1, and 3A1 (Supersomes) as well as insect cell control and rat P450 reductase insect cell
control Supersomes were purchased from BD Gentest (Woburn, MA). The P450s were coexpressed with their corresponding human or rat cytochrome P450 reductase. In addition, human CYP2A6, 2B6, 2C8, 2C9*1, 2C19, 2E1, and 3A4 and rat CYP2B1, 2C11, 2D1, 2E1, and 3A1 were coexpressed with human cytochrome b5. Pooled human liver microsomes, pooled male Sprague-Dawley rat liver microsomes, and NADPH-regenerating systems were also purchased from BD Gentest.

**Animal Pharmacokinetic Studies**

**Animals.** Male Sprague-Dawley rats (250-275 g) were purchased from Harlan Laboratories (Indianapolis, IN). The rats were housed in the animal facility of the School of Pharmacy and were maintained on a 12-hr light/dark cycle at a temperature of 72 ± 2 °F. Food (Purina 5001 Rodent Chow; Purina, St. Louis, MO) and water were available ad libitum. The animal study protocol was approved by the Institutional Animal Care and Use Committee of the School of Pharmacy, University of Maryland. Animal facilities are accredited by the American Association of the Accreditation of Laboratory Animal Care and all experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

**Pharmacokinetics and Brain Distribution Studies of Carboxamides and Benzamides.** The compounds were dissolved in HPBCD solution (10% HPBCD: ethanol (9:1)) for NGB 2904 and JJC 4-077 or PEG 400 solution (30% PEG 400: ethanol (9:1)) for CJB 090 and PG 01037, and a dose of 10 mg/kg was administered intravenously (i.v.) via tail vein or intraperitoneally (i.p) (NGB 2904 and PG01037) to the rats at a volume of 2 mL/kg. These doses were based on a compilation of doses and routes of administration used by numerous investigators studying these compounds.
in vivo. Cohorts of three animals were sacrificed by carbon dioxide asphyxiatiom at predose and 5, 10, 30, 60, 120, 240 and 360 min postdose. Blood was collected by heart puncture using heparinized syringes, centrifuged for 10 min at 10,000 rpm (Denville Scientific 260D, Metuchen, NJ), and the plasma was stored at -80°C until analysis. Brain tissue was immediately excised, blotted dry, weighed, and stored at -80°C until analysis.

Quantification of fluorenyl amides and 2-pyridylphenyl amides. A validated high performance liquid chromatography (HPLC) method with a UV detector was used to quantify the compounds in plasma and brain samples. Preparation of plasma and brain samples involved liquid-liquid extraction methods with organic solvents, ethyl acetate: hexane (3:1, v/v) for NGB 2904 and JJC 4-077, and ethyl acetate: hexane (1:3, v/v) for CJB 090 and PG 01037. Brain samples were homogenized in phosphate-buffered saline using a PowerGen125 from Fisher Scientific (Pittsburgh, PA). A 100 µL aliquot of sample was spiked with internal standard (10 µg/ml of PG 01037 in methanol for NGB 2904 and JJC 4-077; 10 µg/ml of PG 01030 in methanol for CJB 090 and NGB 2904), vortexed slightly, and extracted with 0.9 ml of organic solvents described above. The upper organic layer of 0.8 ml was aliquoted into clean tubes and evaporated to dryness under nitrogen stream at 37°C. The residue was reconstituted with 100 µl of mobile phase, and a 50 µl aliquot was injected into the HPLC system. The HPLC system consisted of a 1525 binary pump and a 717 autosampler from Waters (Milford, MA), and the separation was performed on a Symmetry C-18 analytical column (4.6 × 150 mm, 5 µm) from Waters attached to a C-18 guard column (4.6 × 30 mm, 5 µm) from Phenomenex (Torrance, CA). The mobile phase was an isocratic condition of
acetonitrile and 10 mM ammonium acetate (pH 4.7) [52:48 (v/v) for CJB 090, 46:54 (v/v) for PG 01037, and 68:32 (v/v) for JJC 4-077 and NGB 2904] at a flow rate of 1.0 ml/min. UV detection wavelengths were 283 nm for CJB 090 and PG 01037, 305 nm for JJC 4-077 and 310 nm for NGB 2904. The lower limit of quantification for all compounds was 0.05 µg/ml, with a linearity range of 0.05 – 10 µg/ml. Accuracy and precision of all compounds were determined by replicate injection of quality control samples. Both precision and accuracy of all compounds were of satisfactory results below 15.5% of CV.

Characterization of Human and Rat Cytochrome P450 Enzymes Involved in the Metabolism of NGB 2904 and PG 01037

NGB 2904 and PG 01037 were screened for the enzymes involved in their metabolism. Compounds were incubated with human CYP1A2, 2A6, 2B6, 2C8, 2C9*1(Arg144), 2C19, 2D6*1, 2E1, and 3A4 as well as rat CYP1A2, 2B1, 2C11, 2D1, 2E1, and 3A1 Supersomes for 60 min. For each enzyme tested, the reaction mixture consisted of 50 pmol/ml P450, NADPH-regenerating system (1.3 mM NADP+, 3.3 mM glucose 6-phosphate, 0.4 U/ml glucose-6-phosphate dehydrogenase, and 3.3 mM magnesium chloride), and 10 µM NGB 2904 or PG 01037 in 100 mM potassium phosphate buffer, pH 7.4 (final volume 500 µl). The reactions were initiated by adding ice-cold Supersomes to the prewarmed mixture of buffer, substrate, and cofactors. After a 60-min incubation period at 37°C, the reactions were stopped by the addition of 250 µl of acetonitrile and centrifuged at 10,000 g for 5 min. Two hundred microliters of supernatant was injected onto the HPLC for determination of unchanged compound concentrations. Similar incubations with insect cell control and rat P450 reductase
insect cell control Supersomes were performed to control for the native activities and non-P450-specific effects. Metabolism incubations were performed in triplicate.

**Determination of the Time Course of NGB 2904 and PG 01037 Metabolism**

The time course of metabolism of NGB 2904 and PG 01037 (5 µM final concentration; n = 3) by pooled human liver microsomes and pooled male rat liver microsomes was determined. The microsomes were used at a concentration of 0.8 mg/ml. The cofactor and buffer concentrations were similar to that described above with a final reaction volume of 1500 µl. The reactions were initiated by adding the drug to the prewarmed reaction mixture. After 0, 5, 10, 20, 30, 40, and 60 min of incubation at 37°C, 200 µl of the reaction mixture was sampled, immediately vortexed with 100 µl of acetonitrile to terminate the reaction, and centrifuged at 10,000 g for 5 min. Aliquots of the supernatant were then collected for HPLC analysis.

**DA D3R Compound-Stimulated ATPase Activity**

Drug-stimulated transporter activity was estimated for the D3 receptor antagonists NGB 2904 and PG 01037 by measuring inorganic phosphate released from ATP according to the manufacturer’s protocol (BD Gentest, Woburn, MA). DA D3R compounds were tested at concentrations of 5 – 100 µM. Based on previously published reports this concentration range provides adequate ATPase activation for a majority of compounds (Litman et al., 1997; Polli et al., 2001). Membranes (20 or 25 µg/well) were prepared in Tris-MES buffer, pH 6.8 (50 mM Tris-MES, pH 6.8, 50 mM KCl, 5 mM sodium azide, 2 mM EGTA, and 2 mM DL-dithiothreitol) and incubated at 37°C for 5 min with test compounds or positive controls (Verapamil, 20 µM; PhIP 50 µM; Probenecid, 1 mM) in the presence or absence of 200 or 400 µM sodium orthovanadate.
in triplicate wells on a 96-well plate. The reaction was initiated by the addition of 12 or 15 mM Mg-ATP (20 µl). Incubation time depended on both the species and transporter being analyzed and was carried out according to the manufacturer’s recommendations (BD Gentest, Woburn, MA). The reaction was then terminated by the addition of 10% SDS containing antifoam A. The inorganic phosphate released was detected by incubation at 37°C for 20 min with 200 µl of detection reagent [1:4 v/v mixture of 35 mM ammonium molybdate in 15 mM zinc acetate (pH 5.0) and 10% ascorbic acid]. Phosphate standards were prepared in each plate. The absorbance was measured at 800 nm using a Spectramax Gemini UV-visible spectrophotometer (Molecular Devices, Sunnyvale, CA). The drug-stimulated ATPase activity (pmol/min/mg protein) was determined as the difference between the amounts of inorganic phosphate released from ATP in the absence and presence of vanadate. The drug-stimulated ATPase activity was reported as fold-stimulation relative to the basal ATPase activity in the absence of drug (DMSO control).

**Cell Culture**

MDCK-MDR1 cells were grown at 37 °C, 95% relative humidity and 5% CO₂ atmosphere on 12-well Costar inserts (Transwell; 0.4-μm pore polyester membrane, 1 cm² in diameter). MDCK-MDR1 cells were seeded at a density of 425,000 cells/cm² and cultured for 4 days in 1x Dulbecco's modified Eagle's medium, containing 10% fetal bovine serum, 2% glutamine, 1% nonessential amino acids, 1% penicillin-streptomycin, with the medium changed daily. The formation of restrictive monolayers was monitored by microscopic examination and measurement of transepithelial electrical resistance (TEER) using a Millicell-ERS meter (Millipore Corporation, Billerica, MA).
Characterization of MDCK-MDR1 Cell Monolayers

Expression of P-gp in MDCK-MDR1 Cells

P-gp expression was monitored by Western blot analysis. MDCK-MDR1 total cell lysates were prepared using RIPA buffer (Sigma Aldrich, St. Louis, MO) according to the manufacturer’s protocol. Protein concentration was determined with bicinehoninic acid protein assay kit (Pierce Chemical, Rockford, IL). Cells lysates were resolved on 10% SDS-polyacrylamide precast gels and transferred to a PVDF membrane (Bio-Rad, Hercules, CA). The membrane was blocked in 5% milk and then incubated with C219 anti-Pgp antibody (Calbiochem, Nottingham, UK) diluted 50-fold in buffer overnight at 4°C. The blot was washed, incubated with horseradish peroxidase-conjugated secondary antibody (Amersham Pharmacia Biotech UK, Ltd., Little Chalfont, Buckinghamshire, UK) and then washed again. Bands were visualized by using Enhanced Chemiluminescence (ECL) plus detection system (Amersham Pharmacia Biotech UK, Ltd). Equivalence of protein loading was confirmed by secondary immunoblotting with an anti-β-actin antibody (Sigma, St. Louis, MO).

Evaluation of Monolayer Integrity & Function of P-gp in MDCK-MDR1 Cells

Prior to conducting transport studies, monolayer integrity was determined by measuring the permeability of [14C]-mannitol. Pgp expression was functionally tested by conducting bidirectional transport studies with the P-gp substrate [3H]-saquinavir and determining its efflux ratio across MDCK-MDR1 monolayers.

PG 01037 Bidirectional Transport and Inhibition Studies

These studies were conducted to confirm the results of the ATPase assay and verify that PG 01037 is a P-gp transported substrate. Transport experiments were
performed in both the apical to basolateral (A-B) and the basolateral to apical (B-A) directions across MDCK-MDR1 monolayers in the presence and absence of the P-gp inhibitor verapamil. At the time of the experiment, the culture medium was removed from both the apical and basolateral chambers and the monolayers washed twice with PBS. The monolayers (n = 3/group) were incubated with either 200 µM verapamil in PBS or PBS alone for 30 min. Following the preincubation period, mixtures of 0.1 mM PG 01037 with either 200 µM verapamil in PBS or with PBS alone were added to the donor compartments. The receiver compartments solution consisted of either 200 µM verapamil in PBS (transport in presence of verapamil) or PBS (transport in absence of verapamil). For the apical-to-basolateral study, the inserts were moved to new Transwells containing 1.5 ml of the corresponding receiver compartment solution at 30, 60, 90, and 120 min. For the basolateral-to-apical study, samples were drawn from the apical chamber at the same time points and replaced with equivalent volumes of fresh receiver compartment solution. Transport experiments were performed at 37°C with continuous agitation on a plate shaker (50 cycles/min). Samples were stored at –80°C until the time of analysis.

Data Analysis

**Pharmacokinetic Data Analysis.** The destructive sampling data obtained from the pharmacokinetic studies were analyzed by the naïve averaging method. For a given compound, the plasma concentrations from three animals at each time point were averaged. Compartmental modeling was used to estimate various pharmacokinetic parameters using WinNonlin software (version 4.1, Pharsight Corporation, Mountain View, CA). Several compartmental models were evaluated to determine the best fit.
model. A variety of weighting schemes were also analyzed including equal weight, $1/y$, $1/\hat{y}$, $1/y^2$, and $1/\hat{y}^2$, where $y$ is the observed drug concentration, and $\hat{y}$ is the model-predicted drug concentration. Goodness of fit was based on visual inspection, weighted residual sum of squares, random distribution of residuals, precision of parameter estimates, Akaike's information criteria, and Schwarz criteria. Brain uptake of compounds was represented as a brain to plasma (B/P) concentration ratio in accordance with the equation of $B/P = C_{\text{brain}}/C_{\text{plasma}}$ where $C_{\text{brain}}$ and $C_{\text{plasma}}$ are the concentration in brain and plasma at a specific time point, respectively. Bailer's method was used to calculate the variance associated with both the plasma AUC and brain AUC (Bailer, 1988). The standard error (S.E.) associated with the secondary pharmacokinetic parameter estimates is a measure of the accuracy of the model predictions. Statistical comparisons among plasma and brain AUC values were determined using Student's $t$-test at $p < 0.05$. The $cLogP$ values of the compounds were predicted using ACD/ChemSketch software program (version 11.0, Advanced Chemistry Development, Inc., Toronto, Canada).

**Metabolism Data Analysis.** The human and rat P450 isoforms involved in the metabolism of NGB 2904 and PG 01037 were identified by analyzing the differences in mean substrate concentrations remaining after 60-min incubations. Statistical significance was determined by one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons of P450 incubation versus control incubations. The percentage of the mean control concentration remaining after 60-min incubation was calculated according to the following equation:
% of substrate remaining after 60-min =

$$\frac{C_{\text{cypr, 60 min}}}{C_{\text{average ctrl, 60 min}}} \times 100$$

(1)

where $C_{\text{cypr, 60 min}}$ is the substrate concentration from the $r$th replicate after 60 min of incubation with a particular P450 Supersome, and $C_{\text{average ctrl, 60 min}}$ is the average (n=3) substrate concentration after 60-min incubation with insect cell control Supersomes (for human P450s). The percentages are represented as mean and standard deviation from triplicate reactions.

**Intrinsic clearance calculation.** The intrinsic clearance values were calculated based on the substrate disappearance rate as described previously (Naritomi et al., 2003). The concentration of NGB 2904 and PG 01037 (4 µM) was significantly lower than the $K_m$ value estimated in the pilot study (data not shown). Assuming first-order disappearance of substrate, the disappearance rate constant ($K_d$) was calculated from the slope of log $C_t$ versus time profile based on the following equation:

$$\log C_t = \log C_0 \cdot \frac{K_d \times t}{2.303}$$

(2)

where $C_t$ is the concentration of the substrate at the different time points, and $C_0$ is the substrate concentration at time 0. The initial metabolic rate ($V_0$) (picomoles per minute per picomole of P450 or milligrams of microsomal protein) was calculated from the following equation:

$$V_0 = \frac{K_d \times C_0}{P_{MS}}$$

(3)
where $P_{MS}$ is P450 concentration (picomoles per milliliter) or microsomal protein concentration (milligrams per milliliter). $V_0$ can also be described using Michaelis-Menten equation as follows:

$$V_0 = \frac{V_{max} \times C_0}{K_m + C_0}$$  \hspace{1cm} (4)

Assuming that $C_0 \ll K_m$, eq. 4 can be written as follows:

$$V_0 = \frac{V_{max} \times C_0}{K_m}$$  \hspace{1cm} (5)

Accordingly, the intrinsic clearance was calculated based on the formula:

$$CL_{int} = \frac{V_{max}}{K_m} = \frac{V_0}{C_0}$$  \hspace{1cm} (6)

The intrinsic clearance values were calculated separately from each of the replicates and compared statistically using one-way ANOVA followed by Newman-Keuls post test. $CL_{int}$ values are presented as mean ± S.D. from the three replicates performed for each reaction.

**ATPase Activation Assay Data Analysis.** Only those concentrations of compounds that demonstrate a > 2 fold stimulation were evaluated for being significantly different from the no compound control, as they are representative of a transporter substrate (Polli et al., 2001). Statistical significance was determined by Student’s t-test. (p < 0.05).

**Transport Data Analysis.** The apparent permeability coefficients were determined at sink conditions using the following equation:

$$P_{app} = \frac{dQ/dt}{A \times C_0}$$  \hspace{1cm} (7)
where \( \frac{dQ}{dt} \) is equal to the linear appearance rate of compound in the receiver compartment, \( A \) is the cross-sectional area of the insert filters, and \( C_0 \) is the donor concentration at time 0. All values are represented as mean ± standard deviation from three Transwell inserts. Efflux ratios across the monolayers were calculated using the equation:

\[
\text{Efflux ratio} = \frac{P_{\text{app}}(B - A)}{P_{\text{app}}(A - B)} \quad (8)
\]

where \( P_{\text{app}}(B - A) \) is the permeability from the basolateral to the apical direction and \( P_{\text{app}}(A - B) \) the permeability from the apical to the basolateral direction. The statistical significance of the effect of verapamil on the permeability of PG 01037 was determined with two-tailed Student’s \( t \) test at \( p = 0.05 \).
RESULTS

Physicochemical properties of fluorenyl amides and 2-pyridylphenyl amides

The predicted cLogP, molecular weight, number of hydrogen bond donors, number of hydrogen bond acceptors, and number of freely rotating bonds of NGB 2904, JJC 4-077, CJB 090, and PG 01037 were calculated using ACD/ChemSketch (Table 1). The cLogP of PG 01037 (5.32) was the lowest among four compounds.

Pharmacokinetics of fluorenyl amides after i.v. administration in rats

The observed and the predicted plasma concentrations of NGB 2904 and JJC 4-077 after single i.v. dose administration of 10 mg/kg in male Sprague-Dawley rats was derived based on the best fit achieved with WinNonlin (Figure 2A). The pharmacokinetics of both compounds were best described with a two-compartment model. Secondary pharmacokinetic parameters of NGB 2904 and JJC 4-077 are shown in Table 2. Plasma concentrations of both compounds showed relatively rapid decline in the first hour following dosing and then moderate decline thereafter. Plasma exposure (AUCplasma) of JJC 4-077 (2.13 ± 0.09 hr·µg/ml) was significantly less than that of NGB 2904 (3.45 ± 0.21 hr·µg/ml) (p < 0.05). The elimination half-life, systemic clearance, and volume of distribution of JJC 4-077 (3.27 ± 0.73 hr, 3.44 ± 0.49 l/hr/kg, 14.19 ± 1.59 l/kg, respectively) were higher than that of NGB 2904 (2.60 ± 0.52 hr, 2.46 ± 0.19 l/hr/kg, 7.85 ± 1.14 l/kg, respectively).

Brain uptake of fluorenyl amides after i.v. administration in rats

Brain concentrations of NGB 2904 and JJC 4-077 were significantly higher than plasma concentrations at all sampling time points (p < 0.05) (Figure 2B). Brain concentrations of NGB 2904 and JJC 4-077 remained elevated up to 2 hr post dosing.
and then declined with a moderate elimination phase, which paralleled that of their plasma concentration. The brain exposure (AUC\textsubscript{brain}) of NGB 2904 and JJC 4-077 was significantly different from their plasma exposure (AUC\textsubscript{plasma}) (p < 0.05). Moreover, brain exposure (AUC\textsubscript{brain}) of NGB 2904 (40.78 ± 1.52 hr·µg/ml) was significantly greater than JJC 4-077 (18.62 ± 0.23 hr·µg/ml) (p < 0.05). The overall brain-to-plasma exposure ratios (AUC\textsubscript{brain}/AUC\textsubscript{plasma}) were 11.81 and 8.73 for NGB 2904 and JJC 4-077, respectively. The brain uptake for NGB 2904 ranged from 3.43 to 19.36, and 3.39 to 14.58 for JJC 4-077 (Figure 3A).

**Pharmacokinetics of 2-pyridylphenyl amides after i.v. administration in rats**

The observed and predicted plasma concentration versus time profiles for CJB 090 and PG 01037 are indicated in Figure 2A. The plasma concentrations of CJB 090 rapidly declined after dosing, exhibiting a mono-exponential decay best described by a one-compartment open model. PG 01037 plasma concentrations followed bi-exponential decay and were best described by a two-compartment open model. The secondary pharmacokinetic parameters are listed in Table 2. The elimination half-life of CJB 090 was shorter than that of PG 01037. The plasma AUC of CJB 090 was significantly higher than plasma AUC of PG 01037 (p < 0.05). The systemic clearance of both CJB 090 and PG 01037 was similar. The volume of distribution at steady-state of CJB 090 was less than that of PG 01037.

**Brain uptake of 2-pyridylphenyl amides after i.v. administration in rats**

Brain concentrations of CJB 090 were significantly higher than plasma concentrations at all sampling times, while for PG 01037 significant differences (p < 0.05) were only observed at the later time points (120, 240, and 360 min). While the
brain exposure (AUC\text{brain}) of CJB 090 (23.47 ± 2.38 hr·µg/ml) was significantly greater than PG 01037 (10.97 ± 1.21 hr·µg/ml) (p < 0.05), the brain exposures (AUC\text{brain}) of CJB 090 and PG 01037 were significantly different from their plasma exposure (AUC\text{plasma}) (p < 0.05). Overall AUC\text{brain}/AUC\text{plasma} ratios were 7.19 and 3.92 for CJB 090 and PG 01037, respectively. The brain uptake for CJB 090 ranged from 4.81 to 11.20, and 3.36 to 5.44 for PG 01037 (Figure 3B).

**Pharmacokinetics and brain uptake of NGB 2904 and PG 01037 after \textit{i.p.} administration in rats**

NGB 2904 and PG 01037 were selected for further evaluation of their pharmacokinetics and brain distribution using the \textit{i.p.} route of administration since they both represent a DA D3R antagonist from each of the studied classes (i.e., \textit{fluorenyl amides} and \textit{2-pyridylphenyl amides}) without any partial agonist activity (Table 1) and have strikingly different brain distribution profiles when administered i.v. (Figure 2, Table 2). The pharmacokinetics of NGB 2904 and PG 01037 after \textit{i.p.} administration were best described with a one-compartment model (Figure 2A). The pharmacokinetic parameters for \textit{i.p.} administration are listed alongside the \textit{i.v.} results in Table 2. AUC\text{brain} and AUC\text{plasma} of NGB 2904 and PG 01037 were significantly reduced when compared with the same dose administered \textit{i.v.} (p < 0.05). Compared to \textit{i.v.}, AUC\text{brain} and AUC\text{plasma} ratios were reduced 36% and 25.4% for NGB 2904 and PG 01037, respectively. Comparing the individual \textit{i.v.} and \textit{i.p.} B/P ratios at discrete sampling times, significant differences were observed only at 5 and 120 min for PG 01037 and 5, 30, and 120 min for NGB 2904 (Figure 3A and B). Despite route-dependent differences in brain uptake, brain levels were significantly greater than plasma levels following \textit{i.p.}
administration in accordance with i.v. administration. The clearance values were also increased when the compounds were administered i.p. (Table 2).

**Characterization of Human and Rat Cytochrome P450 Enzymes Involved in the Metabolism of NGB 2904 and PG 01037**

The objective of these studies was to screen for the enzymes involved in the metabolism of NGB 2904 and PG 01037, which were selected as representative compounds for each class. Due to their structural similarities, no class-specific differences are expected in the enzymes involved in the metabolism of these compounds. Among the P450 isoforms tested, rat CYP3A1, CYP2B1, CYP2D1, CYP2C11, and CYP1A2 and human CYP2A6, CYP3A4, CYP2B6, and CYP2E1 were involved in NGB 2904 metabolism (Figure 4A and B). For PG 01037, rat CYP3A1, CYP2C11, CYP1A2 and human CYP3A4 were significantly involved in its metabolism after 60-min incubation compared with the control (p < 0.05) (Figure 4C and D). In accordance with the aforementioned findings rat CYP3A1 and CYP2C11 and human CYP3A4 appeared to be the most significant metabolizing enzymes for these compounds.

**Intrinsic Clearance of NGB 2904 and PG 01037 in Pooled Human and Rat Liver Microsomes.**

Under similar experimental conditions, NGB 2904 and PG 01037 followed first-order reaction kinetics with the concentration of the substrate declining monoexponentially with time. The calculated intrinsic clearance values of both compounds are reported in Table 3. There was no significant difference (p > 0.05) between the intrinsic clearance values of PG 01037 in rat and human liver microsomes.
However, the intrinsic clearance of NGB 2904 in rat liver microsomes was nearly 2-fold higher than in human liver microsomes and 2-fold higher than the intrinsic clearance of PG 01037 in both human and rat liver microsomes (Table 3).

Effect of DA D3R Analogs on Efflux Transporter ATPase Activity

Increasing concentrations of NGB 2904 and PG 01037 were examined to determine their effects on the P-gp, BCRP, and MRP2 ATPase activity. Each compound together with a known excess of ATP was incubated with recombinant human or rat transporter membranes. The compound was classified as a stimulator or inhibitor if the fold stimulation was greater or less than 2-fold compared to the DMSO control (Polli et al., 2001). The positive control compound in each transporter assay significantly (p < 0.05) stimulated inorganic phosphate release with a fold stimulation greater than 2. Treatment with increasing concentrations of PG 01037 but not NGB 2904 produced a dose-dependent fold stimulation of human and rat P-gp (Figure 5A and B, respectively). BCRP and MRP2 ATPase activity were not significantly altered (< 2-fold stimulation) by increasing concentrations of NGB 2904 or PG 01037 (Figure 5C, D, E, F).

PG 01037 Bidirectional Transport and Inhibition Studies in MDCK-MDR1 Cell Monolayers

A high level of P-gp expression was noted in the MDCK-MDR1 cells from each passage used for transport studies (passages 18-24) (Figure 6A). Mannitol permeability ($P_{app}$) ranged from $4.74 \times 10^{-6}$ to $7.01 \times 10^{-6}$ cm/s across MDCK-MDR1 cell monolayers and TEER values were > 400 Ω · cm². Saquinavir efflux ratio was $2.8 \pm 0.06$ and was
significantly decreased ($p < 0.05$) to $1.6 \pm 0.11$ in the presence of verapamil. This validates the existence of functional P-gp in these cell monolayers.

PG 01037 showed polarized transport with a higher B-A permeability ($19.04 \pm 0.09 \times 10^{-6}$ cm/s) than A-B permeability ($4.41 \pm 0.19 \times 10^{-6}$ cm/s). The efflux ratio for PG 01037 was $4.3 \pm 0.24$ (Figure 6B). Verapamil was used to verify the involvement of P-gp in mediating the observed efflux of PG 01037. Verapamil caused a significant ($p < 0.05$) inhibition of P-gp mediated efflux of PG 01037 (ER decreased from 4.3 to 0.9) and increased the A-B permeability of PG 01037 in the MDCK-MDR1 cells (Figure 6B, C). Previous results indicate that 200 µM verapamil does not affect the viability of MDCK-MDR1 cells (Othman et al., 2007).
DISCUSSION

The clinical development of selective DA D3R agents involves optimizing their physical and ‘drug like’ properties to increase bioavailability without diminishing pharmacological efficacy. Additionally, an optimal drug must display an appropriate ADME-Tox profile and achieve adequate concentrations at its target site. The compounds evaluated in this study were developed to achieve Lipinski’s criterion for absorption (Lipinski et al., 2001) while adhering to accepted guidelines for CNS penetration (van de Waterbeemd et al., 1998). SAR studies have shown that optimal pharmacological selectivity and high D3R affinity comes from compounds that have high molecular weights (> 400) and often $cLogP$ values (> 5), predisposing them to have poor bioavailability or unacceptable metabolic profiles. Thus, it is important to identify structural motifs that might be modified to improve the bioavailability of future candidates targeting the DA D3R for therapeutic use.

All four compounds entered the brain quickly and demonstrated high brain penetration when administered i.v. Amongst the physiochemical parameters, $cLogP$ directly correlated with $\text{AUC}_{\text{brain}}/\text{AUC}_{\text{plasma}}$ (Table 1; Table 2) suggesting lipophilicity as a major factor for determining BBB penetration of the structural analogs. In fact, both the fluorenyl amides (NGB 2904 and JJC 4-077) and 2-pyridylphenyl amides (CJB 090 and PG 01037) had brain concentrations that were significantly greater than the corresponding plasma concentrations, with statistically significant higher AUC$_{\text{brain}}$ than AUC$_{\text{plasma}}$ values. The fluorenyl amides displayed relatively higher B/P ratios than those of the 2-pyridylphenyl amides, likely attributed to their higher lipophilicity. Despite possible variation associated with differences in species, dose, and route of
administration, the high brain penetration supports the behavioral data using these compounds in models of yawning, brain stimulation reward and drug seeking behavior (Collins et al., 2005; Gilbert et al., 2005; Martelle et al., 2007; Spiller et al., 2008; Achat-Mendes et al., 2009; Collins et al., 2009; Higley et al., 2010) in the sense that high brain uptake and D3R binding of these compounds are critical to elicit behavioral responses.

The DA D3R analogs displayed plasma half-lives ($t_{1/2}$) in the range of 1.71-3.27 hr, which are substantially longer than cocaine ($t_{1/2} = 0.5$ hr) (Raje et al., 2003) and their elimination from the brain (1.35 – 2.63 hr) is much slower than that of cocaine (0.6 hr) (Raje et al., 2003) (Table 2), which are required characteristics for the inhibition of cocaine’s downstream effects. NGB 2904 and JJC 4-077 are structurally identical except for the presence of a hydroxyl group (3-OH) in the linking chain (Figure 1). The faster systemic clearance of JJC 4-077 compared to NGB 2094 (Table 2) could be the result of enhanced biotransformation of this OH group by phase II enzymes. In contrast, substitution of a fluorenyl amide (NGB 2904 and JJC 4-077) with a 2-pyridylphenyl amide (CJB 090 and PG 01037) did not affect systemic clearance (Table 2).

NGB 2904 has served as a prototypical D3R antagonist in numerous behavioral studies, especially animal models of addiction (Xi and Gardner, 2007). Nevertheless, its poor water solubility and high lipophilicity likely preclude this compound from being a viable candidate for clinical development. NGB 2904 has however served as an important research tool as well as a template for the generation of structurally similar analogs with improved physiochemical properties (Grundt et al., 2007; Newman et al., 2009). For example, substitution of the fluorenyl moiety (NGB 2904 and JJC 4-077) with a 2-pyridylphenyl group (CJB 090 and PG 01037) decreased lipophilicity and
increased DA D3R affinity (Table 1). One of these resulting compounds, PG 01037, is a water soluble and highly potent DA D3R antagonist. Subsequent testing has shown that PG 01037 rapidly enters the brain and localizes in D3- but not D2-receptor rich regions in rat brain (Grundt et al., 2007), a finding supported by relatively low Ki values of PG 01037 for D3 receptors compared to D2 receptors (Table 1).

NGB 2904 and PG 01037 have diverse pharmacokinetic properties (Table 2, i.v. administration) but behave similarly in their ability to attenuate drug-induced behaviors in vivo (Spiller et al., 2008; Higley et al., 2010). Many behavioral evaluations have been conducted using the i.p. route of administration and observed compound-specific behavioral effects from a wide range of doses (i.e. 0.30 – 56.0 mg/kg) (Spiller et al., 2008; Baladi et al., 2010). Thus, there is the possibility that these analogs could differ in their rate and/or extent of absorption from the peritoneal cavity. While brain levels remained substantially higher than plasma levels, there were significant (p < 0.05) decreases in plasma and brain AUCs of both NGB 2904 and PG 01037 after i.p. administration compared to i.v. administration (Table 2, Figure 2). Their clearance values were also increased following i.p. administration (Table 2). Together, these results support the initial supposition of compromised bioavailability and could explain the need for relatively high extravascular drug administration for in vivo action. The limited bioavailability of both compounds after i.p. administration may be due to the influence of dispositional factors such as metabolizing enzymes and drug transporters.

Drug efflux transporters can have significant effects on in vivo disposition and pharmacokinetics of drugs. PG 01037 demonstrated dose-dependent stimulation of both human and rat P-gp ATPase activity, evidenced by an increase in fold-stimulation
values (Figure 5A, B). NGB 2904 did not stimulate P-gp ATPase activity suggesting that replacement of the fluorenlyl moiety of NGB 2904 with the 2-pyridylphenyl group of PG 01037 enhanced brain efflux by increasing P-gp interactions. To confirm the P-gp mediated efflux of PG 01037, *in vitro* transport studies were conducted in the presence and absence of verapamil. Verapamil enhanced A-B permeability and significantly decreased the efflux ratio of PG 01037, indicating that P-gp mediated PG 01037 efflux. P-gp efflux at the BBB could, in part, account for the decreased B/P ratio of PG 01037 compared to NGB 2904 in rats (Table 2). On the other hand, the relatively high lipophilicity (cLogP > 5) of PG 01037 (Table 1) may explain why brain uptake of PG 01037 remained high. MRP2 and BCRP are also expressed at the BBB (Yousif et al., 2007). However, neither NGB 2904 nor PG 01037 modulated their ATPase activity (Figure 5C-F).

In general, compounds administered i.p. are absorbed primarily through the portal circulation and, therefore, must pass through the liver before reaching systemic circulation and target organs (Lukas et al., 1971). The significant decreases in AUC\textsubscript{plasma} and AUC\textsubscript{brain} values of NGB 2904 and PG 01037 following i.p. administration in comparison to *i.v.* administration indicates that these compounds may be metabolized by the liver prior to reaching the brain. The route of administration affected the brain penetration of NGB 2904 to a greater extent than PG 01037 suggesting that NGB 2904 is more susceptible to metabolism, possibly through its fluorenlyl amide linking group (Figure 3). The results of the *in vitro* metabolism study show that human and rat CYP3A subfamilies are primarily involved in the metabolism of both NGB 2904 and PG 01037 (Figures 4A-D). Thus, the liver may be the main site for metabolism of the D3R
analogs when they are administered i.p. Our data further indicate that the intrinsic clearance of NGB 2904 is faster in pooled rat liver microsomes than in pooled human liver microsomes (Table 1) which could be attributed to its substrate specificity for many of the evaluated CYP450 enzymes (Figure 4A-B). The low metabolic stability of NGB 2904 in rats correlates with a rate of systemic clearance that is substantially greater when administered i.p. The overall contribution of drug metabolism to the systemic clearance of NGB 2904 needs to be determined as does its metabolism by Phase II enzymes.

In conclusion, the evolution of D3R agents, beginning with NGB 2904, has led to the development of highly potent D3R compounds. CJB 090 is a D3R partial agonist with a similar D3R selectivity profile to NGB 2904, but somewhat less lipophilic. By replacing the saturated butyl linking chain of CJB 090, the resulting PG01037 is significantly more D3R-selective and a full antagonist. This compound has served as an important tool for in vivo studies, but high doses required for behavioral activity support further optimization. JJC 4-077, like CJB 090 is a partial agonist, but is the most D3R selective ligand in this set. Although the 3-OH group in the linking chain resulted in high D3R selectivity, the studies herein suggest that it may be a metabolic liability suggesting that additional modification at this position might be preferred. In this study, PG 01037 demonstrated the most favorable overall pharmacokinetic profile, BBB permeation, and physicochemical characteristics including improved aqueous solubility. Nevertheless further chemical modification may improve these properties. The 4-phenylpiperazines appear to be a promising class of compounds for further development, however, PG 01037 is characterized by significant P-gp efflux and hepatic
metabolism which is predictive of low bioavailability in humans and provides a plausible explanation for the requirement of high doses for activity in animals. Overall, these studies present critical preclinical information for the design and development of the next generation D3R selective agents for the treatment of drug addiction.
ACKNOWLEDGEMENTS

We would like to thank Dr. Peter Swaan for providing the MDCK-MDR1 cell line.
REFERENCES


FOOTNOTES

a) Unnumbered footnote

This work was supported by the National Institute of Health (NIH) grant [R01 DA16715-03] from the National Institute of Drug Abuse-Intramural Research Program (NIDA-IRP) and by the NIDA Intramural Research Program

b) Send reprint requests to:

Pamela J. Voulalas, Ph.D., School of Pharmacy, University of Maryland, 20 Penn Street, HSFII-559, Baltimore, MD 21201 USA

E-mail: pvoulala@rx.umaryland.edu
LEGENDS FOR FIGURES

Figure 1. Structures of the fluorenyl amides, NGB 2904 and JJC 4-077, and the 2-pyridylphenyl amides, CJB 090, PG 01037, and PG 01030.

Figure 2. Plasma and brain pharmacokinetic profiles of D3R analogs in male Sprague-Dawley rats (n=3/time point). A, observed (mean ± S.D.) and predicted plasma concentration versus time profiles of the fluorenyl amides based on the naïve averaging analysis conducted using WinNonlin. B, observed brain concentrations (mean ± S.D.) versus time profiles of the fluorenyl amides. C, observed (mean ± S.D.) and predicted plasma concentration versus time profiles of the 2-pyridylphenyl amides. D, observed brain concentrations (mean ± S.D.) versus time profiles of the 2-pyridylphenyl amides.

Figure 3. Brain to Plasma ratio (B/P) versus time profiles of the (A) fluorenyl amides, NGB 2904 and JJC 4-077 (n=3) and (B) 2-pyridylphenyl amides, CJB 090 and PG 01037 (n=3).

Figure 4. Metabolism of NGB 2904 (top) and PG 01037 (bottom) by the human recombinant P450s (A and C, respectively) and the rat recombinant P450s (B and D, respectively). Compounds (10 µM) were incubated with Supersomes (50 pmol/ml) and cofactors for 60 min followed by termination of reactions and determination of unchanged substrate. Data are presented as mean percentage of the average control ± S.D. from triplicate reactions. *, p < 0.05 based on Dunnett's test.

Figure 5. Stimulation of human and rat P-gp [A-B, respectively], BCRP [C-D, respectively], and MRP2 [E-F, respectively] ATPase activity by increasing concentrations of NGB 2904 and PG 01037. Stimulation of ATPase activity was estimated by measuring inorganic phosphate released from ATP in the presence or
absence of their respective controls or D3R analogs (NGB 2904 and PG 01037; 5 -100 μM). The drug-stimulated ATPase activity was reported as fold-stimulation relative to the basal ATPase activity in the absence of drug (DMSO control). Data are represented as mean fold stimulation of the average control from triplicate reactions mean ± S.D. *, p < 0.05.

**Figure 6.** Effect of the competitive inhibitor verapamil (200 µM) on the permeability and P-gp mediated efflux of PG 01037 across MDCK-MDR1 monolayers. A, P-gp expression levels over the period in which transport studies were conducted (passages 18-24). B, efflux ratios (mean ± S.D., n = 3) across MDCK-MDR1 monolayers in absence ( - ) and presence ( + ) of verapamil. C, apical-to-basolateral permeability in absence ( - ) and in presence ( + ) of verapamil across MDCK-MDR1 monolayers (data represented as mean ± S.D., n = 3). *, p < 0.05.


**TABLES**

**Table 1.** Predicted physicochemical properties and *in vitro* function data on dopamine D3 receptor of NGB 2904, JJC 4-077, CJB 090 and PG 01037

<table>
<thead>
<tr>
<th>Parameter</th>
<th>NGB 2904</th>
<th>JJC 4-077</th>
<th>CJB 090</th>
<th>PG 01037</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC$_{50}$ (nM)$^a$</td>
<td>14.4 ± 0.5</td>
<td>42.0 ± 1.3</td>
<td>6.3 ± 1.7</td>
<td>3.0 ± 0.7</td>
</tr>
<tr>
<td>(26)$^b$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D2 K$_{in}$ (nM)$^a$</td>
<td>112 ± 22</td>
<td>168 ± 29</td>
<td>24.8 ± 8.6</td>
<td>93 ± 12</td>
</tr>
<tr>
<td>D3 K$_{in}$ (nM)$^a$</td>
<td>2.0 ± 0.4</td>
<td>1.5 ± 0.1</td>
<td>0.4 ± 0.02</td>
<td>0.7 ± 0.1</td>
</tr>
<tr>
<td>Molecular weight (Da)</td>
<td>619.32</td>
<td>583.38</td>
<td>556.26</td>
<td>572.35</td>
</tr>
<tr>
<td>cLogP</td>
<td>7.00</td>
<td>6.55</td>
<td>5.36</td>
<td>5.32</td>
</tr>
</tbody>
</table>

$^a$Grundt et al (Grundt et al., 2007)

$^b$Partial agonist activity: EC$_{50}$ (% stimulation)
Table 2. Pharmacokinetic parameters of NBG 2904, JJC 4-077, CJB 090 and PG 01037 after i.v. and i.p. administration of a 10.0 mg/kg dose. The standard error (S.E.) of the parameter estimate is a measure of the accuracy of the predictions. Brain $t_{1/2}$ was calculated using noncompartmental analysis.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>JJC 4-077 (i.v.)</th>
<th>NGB 2904 (i.v.)</th>
<th>NGB 2904 (i.p.)</th>
<th>CJB 090 (i.v.)</th>
<th>PG 01037 (i.v.)</th>
<th>PG 01037 (i.p.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma $t_{1/2}$ (hr)</td>
<td>3.27 ± 0.73</td>
<td>2.60 ± 0.52</td>
<td>2.58 ± 1.15</td>
<td>1.49 ± 0.13</td>
<td>2.37 ± 0.15</td>
<td>1.83 ± 0.20</td>
</tr>
<tr>
<td>$AUC_{\text{plasma}}$</td>
<td>2.13 ± 0.09</td>
<td>3.45 ± 0.21</td>
<td>0.66 ± 0.07</td>
<td>3.26 ± 0.25</td>
<td>2.80 ± 0.25</td>
<td>2.36 ± 0.14</td>
</tr>
<tr>
<td>$AUC_{\text{brain}}$</td>
<td>18.62 ± 0.23</td>
<td>40.78 ± 1.52</td>
<td>4.97 ± 1.40</td>
<td>23.47 ± 2.38</td>
<td>10.97 ± 1.21</td>
<td>6.91 ± 0.44</td>
</tr>
<tr>
<td>$CL$ (l/hr/kg)</td>
<td>3.44 ± 0.49</td>
<td>2.46 ± 0.19</td>
<td>13.84 ± 3.51</td>
<td>2.91 ± 0.24</td>
<td>2.99 ± 0.09</td>
<td>3.93 ± 0.33</td>
</tr>
<tr>
<td>$V_{ss}$ (l/kg)</td>
<td>14.19 ± 1.59</td>
<td>7.85 ± 1.14</td>
<td>NE</td>
<td>5.95 ± 0.70</td>
<td>9.83 ± 0.47</td>
<td>NE</td>
</tr>
<tr>
<td>$AUC_{\text{brain}}/AUC_{\text{plasma}}$</td>
<td>8.73</td>
<td>11.81</td>
<td>7.55</td>
<td>7.19</td>
<td>3.92</td>
<td>2.93</td>
</tr>
<tr>
<td>Brain $t_{1/2}$ (hr)</td>
<td>2.50</td>
<td>2.48</td>
<td>NE</td>
<td>1.35</td>
<td>2.63</td>
<td>NE</td>
</tr>
</tbody>
</table>

*NE, indicates that this parameter was not estimated with the pharmacokinetic model.
Table 3. Intrinsic clearance values for 5 µM NGB 2904 and PG 01037 in human and male Sprague-Dawley rat-pooled liver microsomes (0.8 mg/ml)

<table>
<thead>
<tr>
<th>Microsomal Preparation</th>
<th>Intrinsic Clearance* (5 µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NGB 2904</td>
</tr>
<tr>
<td>Pooled human liver</td>
<td>29.95 ± 3.83</td>
</tr>
<tr>
<td>microsomes</td>
<td></td>
</tr>
<tr>
<td>Pooled male rat liver</td>
<td>55.85 ± 3.05&lt;sup&gt;a,b&lt;/sup&gt;</td>
</tr>
<tr>
<td>microsomes</td>
<td></td>
</tr>
</tbody>
</table>

*Intrinsic clearance is reported as microliters per minute per milligram of protein (n=3/reaction)

<sup>a</sup>, <i>p</i> < 0.05 based on Newman-Keuls test compared to intrinsic clearance of NGB 2904 pooled human and male rat liver microsomes.

<sup>b</sup>, <i>p</i> < 0.05 based on Newman-Keuls test compared to intrinsic clearance of NGB 2904 pooled male rat liver microsomes and PG 01037 pooled human and rat liver microsomes.
Figure 3

A

- JJC 4-077 10 mg/kg i.v.
- NGB 2904 10 mg/kg i.v.
- NGB 2904 10 mg/kg i.p.

Brain to Plasma Ratio

<table>
<thead>
<tr>
<th>Time (min)</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>120</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>240</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>360</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

- CJB 090 10 mg/kg i.v.
- PG 01037 10 mg/kg i.v.
- PG 01037 10 mg/kg i.p.

Brain to Plasma Ratio

<table>
<thead>
<tr>
<th>Time (min)</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>120</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>240</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>360</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 4

A

% of NGB 2904 remaining after 60 min incubation

Control  CYP1A2  CYP2C9  CYP2C8  CYP2D6  CYP2A6  CYP2B6  CYP2E1  CYP2C19

B

% of NGB 2904 remaining after 60 min incubation

Control  CYP3A1  CYP2B1  CYP2D1  CYP2C11  CYP1A2  CYP2E1

C

% of PG 01037 remaining after 60 min incubation

Control  CYP1A2  CYP2C9  CYP2C8  CYP2D6  CYP2A6  CYP2B6  CYP2E1  CYP2C19

D

% of PG 01037 remaining after 60 min incubation

Control  CYP3A1  CYP2B1  CYP2D1  CYP2C11  CYP1A2  CYP2E1
Figure 5

A  hMDR1

B  rMdr1a

C  hBCRP

D  rBcrp

E  hMRP2

F  rMrp2